6-(4-morpholin-4-ylmethylphenyl)pyrrolo[2,3-b]pyridine-1-carboxylic acid amide | 1542067-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(4-morpholin-4-ylmethylphenyl)pyrrolo[2,3-b]pyridine-1-carboxylic acid amide
• 英文别名: 6-[4-(morpholinomethyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxamide；6-[4-(Morpholin-4-ylmethyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxamide；6-[4-(morpholin-4-ylmethyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxamide
• CAS: 1542067-17-3
• 化学式: C₁₉H₂₀N₄O₂
• 分子量: 336.393
• InChiKey: QHIIDJMYFYGHEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  73.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-[[4-(1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl]morpholine 在 四丁基溴化铵 、 碳酸氢铵 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 10.0h， 生成 6-(4-morpholin-4-ylmethylphenyl)pyrrolo[2,3-b]pyridine-1-carboxylic acid amide
  参考文献：
  名称：

  7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors

  摘要：

  7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors. The compounds displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects. A selected compound (1l; ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp. In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compound exhibited an effect similar to that of Olaparib in terms of tumor volume inhibition when used at a lower dose than the reference compound. Treatment was well tolerated, as no deaths or significant weight losses were observed among the treated animals. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.12.031

文献信息

• [EN] 7-AZAINDOLE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS DE 7-AZAINDOLE UTILISÉS EN TANT QU'INHIBITEURS DE PARP
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2015011008A1

  公开（公告）日：2015-01-29

  The present invention relates to 7-azaindole derivatives of Formula (I), pharmaceutical compositions containing such derivatives. The invention further relates to said pharmaceutical compositions for use in medicine, and more particularly in the treatment of cancer diseases where an inhibition of PARP is responsive.

  本发明涉及公式（I）的7-氮杂吲哚衍生物，包含这种衍生物的药物组合物。该发明进一步涉及用于医学用途的上述药物组合物，更具体地用于治疗癌症疾病，其中对PARP的抑制是有效的。
• 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
  作者：Raffaella Cincinelli、Loana Musso、Lucio Merlini、Giuseppe Giannini、Loredana Vesci、Ferdinando M. Milazzo、Nives Carenini、Paola Perego、Sergio Penco、Roberto Artali、Franco Zunino、Claudio Pisano、Sabrina Dallavalle

  DOI：10.1016/j.bmc.2013.12.031

  日期：2014.2

  7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors. The compounds displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects. A selected compound (1l; ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp. In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compound exhibited an effect similar to that of Olaparib in terms of tumor volume inhibition when used at a lower dose than the reference compound. Treatment was well tolerated, as no deaths or significant weight losses were observed among the treated animals. (C) 2013 Elsevier Ltd. All rights reserved.